 I. To establish the maximum tolerated dose MTD of the combination of romidepsin, rituximab and lenalidomide in patients with relapsedrefractory B-cell non-Hodgkin lymphoma NHL. Phase I II. To assess the overall response rate ORR of this combination in patients with transformed follicular lymphoma FL. Phase II 